Advances in immunotherapy for Alzheimer's Disease 2020-2023 – a literature review

Abstract

Introduction: Alzheimer's disease is an increasing problem in aging European
societies. Almost 9 million Europeans already suffer from this disease.
The aim of this article is to provide an objective overview of new immunotherapy and
vaccination methods among published research results from 2020-2023.
Materials and methods: This paper is based on medical articles collected in the
PubMed database from 2020-2023. The research was conducted by analyzing keywords such
as: "Alzheimer Disease," "Immunotherapy"/"Vaccination" and "Treatment."
Results: Recent years have seen a large increase in research directed at AD
immunotherapy. Among these, those on aducanumab, donanemab and lecanemab are
particularly noteworthy. Lecanemab and aducanumab are already registered in the US, among
others. More studies should be expected to try to solve the problems of qualifying patients into
the appropriate groups or increasing the number of variables in ongoing trials. This will allow
an even more reliable evaluation of the molecules under study and, consequently, further
registrations of medicinal products.